

# Jörg Hanrieder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/506767/publications.pdf>

Version: 2024-02-01

40  
papers

1,444  
citations

236925

25  
h-index

330143

37  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging mass spectrometry in drug development and toxicology. Archives of Toxicology, 2017, 91, 2283-2294.	4.2	90
2	Novel Trimodal MALDI Imaging Mass Spectrometry (IMS3) at 10 $\mu$ m Reveals Spatial Lipid and Peptide Correlates Implicated in A $\beta$ Plaque Pathology in Alzheimer's Disease. ACS Chemical Neuroscience, 2017, 8, 2778-2790.	3.5	84
3	Imaging Mass Spectrometry in Neuroscience. ACS Chemical Neuroscience, 2013, 4, 666-679.	3.5	83
4	L-DOPA-induced Dyskinesia is Associated with Regional Increase of Striatal Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry. Molecular and Cellular Proteomics, 2011, 10, M111.009308.	3.8	76
5	Neonatal Exposure to the Cyanobacterial Toxin BMAA Induces Changes in Protein Expression and Neurodegeneration in Adult Hippocampus. Toxicological Sciences, 2012, 130, 391-404.	3.1	76
6	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2017, 8, 347-355.	3.5	66
7	Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. Analytical Chemistry, 2017, 89, 4685-4694.	6.5	60
8	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2018, 9, 1802-1817.	3.5	60
9	Imaging Mass Spectrometry Reveals Elevated Nigral Levels of Dynorphin Neuropeptides in L-DOPA-Induced Dyskinesia in Rat Model of Parkinson's Disease. PLoS ONE, 2011, 6, e25653.	2.5	60
10	MALDI imaging of post-mortem human spinal cord in amyotrophic lateral sclerosis. Journal of Neurochemistry, 2013, 124, 695-707.	3.9	50
11	Pyroglutamation of amyloid- $\beta$ 42 (A $\beta$ 42) followed by A $\beta$ 1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732.	3.4	49
12	MALDI mass spectrometry based molecular phenotyping of CNS glial cells for prediction in mammalian brain tissue. Analytical and Bioanalytical Chemistry, 2011, 401, 135-147.	3.7	46
13	Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA. Archives of Toxicology, 2015, 89, 423-436.	4.2	42
14	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
15	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals A $\beta$ Aggregation Dependent Anionic Lipid Accumulations and Metabolism. Analytical Chemistry, 2018, 90, 8130-8138.	6.5	39
16	MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease. Journal of Visualized Experiments, 2012, .	0.3	38
17	Lithium Accumulates in Neurogenic Brain Regions as Revealed by High Resolution Ion Imaging. Scientific Reports, 2017, 7, 40726.	3.3	37
18	Probing amyloid- $\beta$ pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry. Journal of Neurochemistry, 2016, 138, 469-478.	3.9	34

#	ARTICLE	IF	CITATIONS
19	Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. <i>Journal of Neurochemistry</i> , 2019, 151, 488-506.	3.9	34
20	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	6.2	32
21	Spatial neuroproteomics using imaging mass spectrometry. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 718-731.	2.3	31
22	Spatial Elucidation of Spinal Cord Lipid- and Metabolite- Regulations in Amyotrophic Lateral Sclerosis. <i>Scientific Reports</i> , 2014, 4, 5266.	3.3	31
23	Time-of-Flight Secondary Ion Mass Spectrometry Based Molecular Histology of Human Spinal Cord Tissue and Motor Neurons. <i>Analytical Chemistry</i> , 2013, 85, 8741-8748.	6.5	30
24	High Resolution Metabolite Imaging in the Hippocampus Following Neonatal Exposure to the Environmental Toxin BMAA Using ToF-SIMS. <i>ACS Chemical Neuroscience</i> , 2014, 5, 568-575.	3.5	30
25	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 458-467.	2.3	30
26	Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia. <i>Molecular Neurodegeneration</i> , 2021, 16, 47.	10.8	27
27	The <i>Uppsala APP</i> deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid $A\beta$ fibril formation. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	23
28	Following spatial $A\beta$ aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. <i>Science Advances</i> , 2021, 7, .	10.3	22
29	Aggregated $A\beta_{1-42}$ Is Selectively Toxic for Neurons, Whereas Glial Cells Produce Mature Fibrils with Low Toxicity in <i>Drosophila</i> . <i>Cell Chemical Biology</i> , 2018, 25, 595-610.e5.	5.2	21
30	Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. <i>Journal of Neurochemistry</i> , 2022, 160, 482-498.	3.9	17
31	Chemical imaging of evolving amyloid plaque pathology and associated $A\beta$ peptide aggregation in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 152, 602-616.	3.9	15
32	Computational Analysis of Alzheimer Amyloid Plaque Composition in 2D- and Elastically Reconstructed 3D-MALDI MS Images. <i>Analytical Chemistry</i> , 2020, 92, 14484-14493.	6.5	15
33	MALDI imaging delineates hippocampal glycosphingolipid changes associated with neurotoxin induced proteopathy following neonatal BMAA exposure. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 740-746.	2.3	12
34	Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 2278-2288.	2.8	11
35	Comprehensive multiplexed protein quantitation delineates eosinophilic and neutrophilic experimental asthma. <i>BMC Pulmonary Medicine</i> , 2014, 14, 110.	2.0	8
36	MALDI Imaging Mass Spectrometry: Neurochemical Imaging of Proteins and Peptides. <i>Neuromethods</i> , 2019, , 179-197.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Association of PTHrP levels in CSF with Alzheimer's disease biomarkers. <i>Clinical Mass Spectrometry</i> , 2019, 14, 124-129.	1.9	5
38	Herpes Simplex Virus 1 and 2 Infections during Differentiation of Human Cortical Neurons. <i>Viruses</i> , 2021, 13, 2072.	3.3	5
39	Amyloid fibril polymorphism and cell-specific toxicity <i>in vivo</i> . <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 136-137.	3.0	3
40	Preface: Mass spectrometry in Alzheimer disease. <i>Journal of Neurochemistry</i> , 2021, 159, 207-210.	3.9	1